The NAD+ Ceiling: Where NMN and NR Supplementation Plateaus, and What Lies Beyond

The NAD+ supplementation category — nicotinamide mononucleotide, nicotinamide riboside, and their adjacent precursors — has been the most successful single intervention the longevity supplement market has produced. The biological rationale is well documented. NAD+ levels decline with age. The decline is associated with reduced sirtuin activity, impaired mitochondrial function, and accumulation of cellular damage. Supplementation with NAD+ precursors raises NAD+ levels measurably. The question that the second decade of the NAD+ era is forcing into view is what happens after that.

The clinical literature on NMN and NR is broadly consistent. NAD+ levels in serum and tissue rise with supplementation. Sirtuin activity rises with NAD+ availability. Mitochondrial function shows measurable improvement in some compartments. Functional outcome data — the kind of data that would link the biomarker effect to longevity in human subjects — is, as of 2023, still limited.

The ceiling, mechanistically

The ceiling that NAD+ precursor supplementation encounters has a specific mechanistic shape. Raising the substrate available to a pathway is helpful only insofar as the pathway is substrate-limited. Many of the cellular regulatory effects that NAD+ supports are not principally substrate-limited; they are regulated by gene expression patterns, by post-translational modification, and by upstream signalling that does not depend on substrate availability past a baseline threshold.

In the simplest framing: NAD+ supplementation raises a floor. It does not raise a ceiling. Once the substrate is sufficient, additional substrate does not produce additional effect. The biology has moved on to a regulatory question — which genes are expressed, in what tissues, under what conditions — that NMN and NR do not directly address.

“NAD+ supplementation raises a floor. It does not raise a ceiling. The biology has moved on to a regulatory question that NMN and NR do not directly address.”

Where the bioregulator framework sits relative to this

The peptide-class bioregulator research lineage — four decades of work centred at Saint Petersburg and now distributed across collaborating institutions — operates at the regulatory layer that NAD+ supplementation does not directly reach. Short-chain regulatory peptides are proposed to modulate tissue-specific gene expression patterns, including, among many other effects, the patterns that govern mitochondrial biogenesis, sirtuin-family activity, and the broader cellular response to oxidative stress and glycation.

This is not a replacement framing. NAD+ precursors and bioregulator compounds are not in competition for the same biological function. They occupy different layers of the same regulatory cascade. A reasonable mechanistic reading is that NAD+ availability is necessary but not sufficient for the cellular outcomes the longevity category targets, and that regulatory peptides act on the sufficient layer that NAD+ supplementation cannot reach on its own.

What this means for the longevity supplement consumer

The longevity supplement consumer in 2023 is unusually well informed. They have read the Sinclair literature. They know the NMN dose-response data. They are aware of the limitations of the available human evidence. Many of them have been supplementing for two or more years and are beginning to ask the question that the category has been slow to answer: what comes next, in mechanism rather than in product.

The bioregulator framework is one of the substantive answers. Not the only one. Senolytics, peptide-class compounds, partial reprogramming research, and the broader Hallmarks of Aging programme all describe layers of the same regulatory architecture that NAD+ supplementation operates on. The longevity supplement category as currently constituted is not organised to deliver any of these reliably at consumer scale. That organisational gap is part of why the Opticeutical category is being defined.

A note on what this is not

This is not a recommendation against NMN or NR supplementation, and it is not a clinical position on either compound. NAD+ precursors are well-studied, broadly safe at typical consumer doses, and continue to have a place in the supplementation stack of consumers whose floor is genuinely low. The point of this note is not to disparage the category but to describe the ceiling it appears to be approaching, and to position the bioregulator framework relative to that ceiling. Further treatment of the underlying biology is documented at endogenicpharmacology.com.